pulmonary arterial hypertension
Conditions
Interventions
Experimental group, 38 patients with pulmonary arterial hypertension, will visit at visit 1: clinical evaluation that investigates the symptoms and medications previously used, will be done by intervi
Drug
Procedure/surgery
E07.605.750
G11.427.410.698.277
Sponsors
Universidade Federal do Rio Grande do Sul
Fundo de Incentivo à Pesquisa e Eventos (FIPE)
Eligibility
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients diagnosed with pulmonary arterial hypertension according to the Nice classification, 2013, confirmed by right cardiac catheterization at rest. Stable drug treatment in the last 3 months. Symptomatic, with dyspnoea. In functional class of the New York Heart Association II and III.
Exclusion criteria
Exclusion criteria: Non-HAP Pulmonary Hypertension, that is, Groups 2 to 5 will be excluded, as well as patients with other comorbidities that may cause limitation of exercise capacity. Use of prolonged home oxygen therapy. That they present FEV1VF <0.7. Be involved in regular physical activity programs in the last 3 to 6 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Dyspnea assessed by the Borg categorical scale during isotype (highest common time in all tests) in high intensity constant load ECT (cardiopulmonary exercise test) comparing inhaled bronchodilator, furosemide and placebo. | — |
Secondary
| Measure | Time frame |
|---|---|
| 510/5000 Expected outcome 1: In isotherm and isoventilation, during high intensity constant load TECP, contrasting the 3 interventions. Improvement of parameters of respiratory mechanics: inspiratory capacity (IC); inspiratory reserve volume (VRI); final inspiratory pulmonary volume (FVII) / total lung capacity (CPT); VT / CI limitation to expiratory flow (LFE) evaluated by the percentage of overlap of the VT expiratory flow loop over the maximum flow-volume loop (flow-volume loop technique);;Expected outcome 2: Decreased pain in lower limbs (Borg categorical scale);;Expected outcome 3: Improvement in noninvasive hemodynamic variables (oxygen pulse, heart rate and HR / VO2 ratio).;Expected outcome 4: Decrease of exercise tolerance time (Tlim) during constant load ECT comparing the 3 interventions.;Expected outcome 5: In the incremental cardiopulmonary exercise test to evaluate the correlation between the variation of rest and peak of exercise of the following variables: Improvement of parameters of respiratory mechanics and variables of invasive hemodynamics (pulmonary artery pressure, pulmonary vascular resistance, cardiac output; cardiac index, systolic volume, pulmonary vascular compliance, right ventricular work index);;Expected outcome 6: Improvement of parameters of respiratory mechanics during exercise with parameters of resting pulmonary function: forced expiratory volume in the first second (FEV1); FEV1 / forced vital capacity (FVC); forced expiratory flow between 25-75% of FVC (FEF25-75%); LFE (flow-volume loop technique); pulmonary volumes measured by body plethysmography and pulmonary diffusion capacity of carbon monoxide (DLCO). | — |
Countries
Brazil
Contacts
Public ContactElisa Schroeder
Universidade Federal do Rio Grande do Sul
Outcome results
None listed